Genetic and Epigenetic Landscape for Drug Development in Polycystic Ovary Syndrome

• Published in: Endocrine reviews Vol. 45; no. 4; pp. 437 - 459
• Main Authors: Chen, Yi, Wang, Guiquan, Chen, Jingqiao, Wang, Congying, Dong, Xi, Chang, Hsun-Ming, Yuan, Shuai, Zhao, Yue, Mu, Liangshan
• Format: Journal Article
• Language: English
• Published: United States 12.07.2024
• Subjects: Drug Development; Epigenesis, Genetic - drug effects; Female; Humans; Medicin och hälsovetenskap; Polycystic Ovary Syndrome - drug therapy; Polycystic Ovary Syndrome - genetics; gene therapy; genetics; pharmacotherapy; epigenetics; polycystic ovary syndrome
• ISSN: 0163-769X; 1945-7189; 1945-7189
• DOI: 10.1210/endrev/bnae002

The treatment of polycystic ovary syndrome (PCOS) faces challenges as all known treatments are merely symptomatic. The US Food and Drug Administration has not approved any drug specifically for treating PCOS. As the significance of genetics and epigenetics rises in drug development, their pivotal insights have greatly enhanced the efficacy and success of drug target discovery and validation, offering promise for guiding the advancement of PCOS treatments. In this context, we outline the genetic and epigenetic advancement in PCOS, which provide novel insights into the pathogenesis of this complex disease. We also delve into the prospective method for harnessing genetic and epigenetic strategies to identify potential drug targets and ensure target safety. Additionally, we shed light on the preliminary evidence and distinctive challenges associated with gene and epigenetic therapies in the context of PCOS.